June 8, 2015. BUFFALO, N.Y. — A study led by University of Buffalo and Roswell Park Cancer Institute researchers claims to have identified beliefs and personality traits associated with higher levels of distress in newly diagnosed prostate cancer patients. The study's authors say their findings support the value of emotional and informational support for patients and perhaps early counseling for some who are the most distressed.

Heather Orom, PhD, University of Buffalo
Heather Orom, PhD
“Several studies have examined distress in prostate cancer patients after treatment," said lead author Heather Orom PhD, an assistant professor of community health and health behavior in University of Buffalo's School of Public Health and Health Professions. "But few of these studies," Orom said, "assessed distress in men early in diagnosis, before receiving treatment." ...continue reading Prostate Cancer Diagnosis Calls for Early Support So That Men Can Make Smart Treatment Decisions, Study Says

June 3, 2015. Radium-223, brand name Xofigo (formerly Alpharadin), is an FDA approved intravenous injectable treatment for painful bone metastases in men with castration-resistant prostate cancer (CRPC). The drug Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. Radium-223 is taken by intravenous injection once a month (every four weeks) for up to six months. Radium-223 received priority review two years ago based on its ability to extend Overall Survival as shown in its Phase 3 trial. ...continue reading Radium-223 linked to longer overall survival in patients with castration-resistant prostate cancer with bone metastases

May 18, 2015— AUA, New Orleans. A study of medical records of nearly 10,000 patients with prostate cancer shows that active surveillance (the updated form of watchful waiting) is suitable for most men with low-risk disease. Twelve to 15 years after diagnosis, these men are no more likely to die of prostate cancer than of other conditions and diseases. By contrast, the study shows, to avoid dying of prostate cancer men with high-risk disease may require aggressive "multimodal treatment" including surgery. ...continue reading Active Surveillance For Low-Risk Prostate Cancer Does Not Shorten Life

June 2, 2015. Primary androgen deprivation therapy for localized prostate cancer increases diabetes risk by up to 60 per cent, particularly in men under 70 years of age, according to research published in the June issue of The Journal of Urology.

"As the benefits of primary androgen deprivation therapy for localized prostate cancer are controversial," the authors say, "and most prostate cancer survivors are of advanced age with comorbidities, it is important to determine if primary androgen deprivation therapy increases the risk of diabetes and to determine the susceptibility factors." ...continue reading Diabetes Risk For Men Treated With Primary Androgen Deprivation for Localized Prostate Cancer

Already available, designed to reduce unneeded biopsies
May 18, 2015 ANN ARBOR, Mich. — A new urine-based test improves prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.

The test, developed at the University of Michigan Comprehensive Cancer Center, is called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, T2:ERG and PCA3, both of which can be detected through a urine sample. The test has been available clinically since September 2013. ...continue reading Urine-Based Test Improves on PSA for Detecting Prostate Cancer

May help determine specialized treatment

PSA Rising via TORONTO, Canada – May 27, 2015 – Prostate cancer researchers in Canada have drawn a molecular portrait that provides the first complete picture of localized, multi-focal disease within the prostate and also unveils a new gene subgroup driving it.

...continue reading Gene Subgroup C-MYC in Aggressive Gleason 7 Prostate Cancer

Indications for Prostate Biopsy

Digital Rectal Exam (DRE)
suspicious for cancer at any PSA level
PSA above 3 ng/mL High Risk of prostate cancer based on multiple risk factors.
TRUS (transrectal ultrasound) Guided Biopsy. In some circumstances, Doppler ultrasound- guided or MRI-guided biopsy may be preferred or required. If TRUS-guided-biopsy not done, follow up in 6 to 12 months with PSA/DRE. Consider testing FPSA, PHI, and/or PCA3 if PSA is between 3 and 10 ng/mL. Measure free PSA (FPSA), PHI (Prostate Health Index), or PCA3 in patients with PSA 3 - 10 ng/mL

...continue reading Biopsy to Detect Prostate Cancer – when is it needed?

Keep walking
Keep Walking
For cancer patients, a brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.

Brad Behnke, associate professor of exercise physiology at Kansas State University has shown together with colleagues that moderate exercise on a regular basis enhances tumor oxygenation. Getting more oxygen into a tumor may improve treatments in cancer patients. ...continue reading Moderate Exercise May Make Cancer Treatments More Effective